Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma:HCCSC C01 Trial

NCT05282433 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT05282433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05282433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma:HCCSC C01 Trial
Lead sponsor
Zhongnan Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 16, 2022
Completion date
December 31, 2024
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma; targeted therapy; progression-free survival